VinaR - Repository of the Vinča Nuclear Institute
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrilic)
    • Serbian (Latin)
  • Login
View Item 
  •   Vinar
  • Vinča
  • WoS Import
  • View Item
  •   Vinar
  • Vinča
  • WoS Import
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Lipoprotein Subfractions in Metabolic Syndrome and Obesity: Clinical Significance and Therapeutic Approaches

Thumbnail
2013
5376.pdf (420.2Kb)
Authors
Nikolić, Dragana
Katsiki, Niki
Montalto, Giuseppe
Isenović, Esma R.
Mikhailidis, Dimitri P.
Rizzo, Manfredi
Review
Metadata
Show full item record
Abstract
Small, dense low density lipoprotein (sdLDL) represents an emerging cardiovascular risk factor, since these particles can be associated with cardiovascular disease (CVD) independently of established risk factors, including plasma lipids. Obese subjects frequently have atherogenic dyslipidaemia, including elevated sdLDL levels, in addition to elevated triglycerides (TG), very low density lipoprotein (VLDL) and apolipoprotein-B, as well as decreased high density lipoprotein cholesterol (HDL-C) levels. Obesity-related co-morbidities, such as metabolic syndrome (MetS) are also characterized by dyslipidaemia. Therefore, agents that favourably modulate LDL subclasses may be of clinical value in these subjects. Statins are the lipid-lowering drug of choice. Also, anti-obesity and lipid lowering drugs other than statins could be useful in these patients. However, the effects of anti-obesity drugs on CVD risk factors remain unclear. We review the clinical significance of sdLDL in being overweig...ht and obesity, as well as the efficacy of anti-obesity drugs on LDL subfractions in these individuals; a short comment on HDL subclasses is also included. Our literature search was based on PubMed and Scopus listings. Further research is required to fully explore both the significance of sdLDL and the efficacy of anti-obesity drugs on LDL subfractions in being overweight, obesity and MetS. Improving the lipoprotein profile in these patients may represent an efficient approach for reducing cardiovascular risk.

Keywords:
lipoproteins / small dense low density lipoprotein / obesity / metabolic syndrome / obesity treatment / anti-obesity drugs / lipid-lowering drugs
Source:
Nutrients, 2013, 5, 3, 928-948
Projects:
  • Hormonal regulation of expression and activity of the nitric oxide synthase and sodium-potassium pump in experimental models of insulin resistance, diabetes and cardiovascular disorders (RS-173033)
  • Genzyme, Pfizer, Novartis, MSD, Abbott, Astra-Zeneca, Bracco, Bromatech, Chiesi Farmaceutici, Novo-Nordisk, Rikrea, Servier

DOI: 10.3390/nu5030928

ISSN: 2072-6643 (print)

PubMed: 23507795

WoS: 000316610400019

Scopus: 2-s2.0-84875303002
[ Google Scholar ]
96
94
URI
http://vinar.vin.bg.ac.rs/handle/123456789/5380
Collections
  • WoS Import
Institution
Vinča

DSpace software copyright © 2002-2015  DuraSpace
About VinaR - Repository of the Vinča Institute of Nuclear Sciences | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceInstitutionsAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About VinaR - Repository of the Vinča Institute of Nuclear Sciences | Send Feedback

OpenAIRERCUB